[Effects of raloxifene on bone biomarkers in postmenopausal women on maintenance haemodialysis].

Abstract

Postmenopausal women on maintenance haemodialysis (MHD) has considerably higher risk of bone fracture than general population with combination of postmenopausal osteoporosis and renal osteodystrophy. However, the treatment of osteoporosis on MHD has not been established. Evidence indicates raloxifene (RLX), a selective estrogen receptor modulator, is effective for a protection of bone fracture without increasing of breast cancer and endometrial cancer. We hereby report short-term use experience of RLX for the postmenopausal MHD patients. Fifteen postmenopausal MHD patients with less than 80% of YAM bone density in DEXA administrated 60 mg RLX on every HD days (3 days/week). Serum NTX level significantly decreased after 6 months (180 +/- 18 vs. 95 +/- 12 nmol/BCE/L, p< 0.05), however, i-PTH did not have the significant difference. (115 +/- 23 vs. 157 +/- 29 pg/mL). RLX is effective for bone biomarker improvement in postmenopausal MHD patients. Further evaluation for the effectiveness and safety of RLX is necessary in the long term.

• Authors: Kenzo Matsuo, Michiyo Fujinaga, Kuniyoshi Tsuchiya, Masahiko Nakamoto, Chikao Yasunaga
• Journal: Clinical calcium (Clin Calcium) Vol. 15 Suppl 1 Pg. 92-6; discussion 96-7 (Sep 2005) ISSN: 0917-5857 [Print] Japan
• PMID: 16272639 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Biomarkers
• Collagen Type I
• Peptides
• Selective Estrogen Receptor Modulators
• collagen type I trimeric cross-linked peptide
• Raloxifene Hydrochloride
• Collagen

Topics

• Aged
• Aged, 80 and over
• Biomarkers (blood)
• Bone Density
• Collagen (blood)
• Collagen Type I
• Drug Administration Schedule
• Female
• Fractures, Spontaneous (etiology, prevention & control)
• Humans
• Middle Aged
• Osteoporosis, Postmenopausal (complications, drug therapy, metabolism)
• Peptides (blood)
• Raloxifene Hydrochloride (administration & dosage)
• Renal Dialysis (adverse effects)
• Risk
• Selective Estrogen Receptor Modulators (administration & dosage)